Identification of a novel DNA aptamer that selectively targets lung cancer serum. Issue 53 (15th October 2021)

• Record Type: Journal Article
• Authors: Zhao, Yunwang; He, Lei; Huang, Baihai; Zhang, Weidong; Hu, Ailing; Li, Baolin; Liao, Shiqi; Wang, Na
• Is Part Of: RSC advances. Volume 11:Issue 53(2021)
• Page Start: 33759
• Page End: 33769
• Publication Date: 2021-10-15
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d1ra06233f
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : Lung cancer is the leading cause of cancer-related deaths worldwide. Abstract : Lung cancer is the leading cause of cancer-related deaths worldwide. Early diagnosis and treatment is critical to improving the 5 year survival rate of lung cancer. The identification of new options for early-stage diagnosis and therapy of lung cancer still represents a crucial challenge. Therefore, a new diagnostic method is urgently needed. In this study, we used a new modified SELEX, called serum-SELEX, to isolate aptamers that can specifically bind lung cancer serum, without any prior knowledge of their target. Among the obtained candidate aptamer sequences, Ap-LC-19 was identified as the optimal aptamer probe with the lowest dissociation constant ( K d ) value of 15 ± 8.6 nM and higher affinity assessed by qPCR. Furthermore, this molecule could be a suitable aptamer for lung cancer serum and could be used as a recognition element in aptamer-based biosensors for efficient early diagnosis of lung cancer or as an innovative tool for targeted therapy. In addition, we performed MALDI-TOF MS followed by secondary peptide sequencing MS analysis for the identification of the aptamer targeted proteins. CLEC3B could be useful biomarkers for early detection of lung cancer and in monitoring its evolution.